|drug240||Analysis of cytokine response, innate and adaptive immune response, complement activation, and serum neurofilaments as a marker of neurological damage. Wiki||0.58|
|D051437||Renal Insufficiency, NIH||0.26|
|D008107||Liver Diseases NIH||0.20|
|D045169||Severe Acute Respiratory Syndrome NIH||0.03|
There are 3 clinical trials
The purpose of this study is to characterize the single-dose plasma and urine PK of TAK-788 and its active metabolites (AP32960 and AP32914) in participants with severe RI compared to matched-healthy participants with normal renal function.
The purpose of this study is to characterize the single-dose plasma PK of TAK-788 and its active metabolites (AP32960 and AP32914) in participants with moderate and/or severe HI compared to matched-healthy participants with normal hepatic function.
The purpose of this study is to characterize the effect of a high-fat meal on the PK of TAK-788 administered in healthy participants.
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports